Company intelligence / Profile preview

Nebula Genomics

Garden City, New York, United States

Ownership: Private
Development stage: Other

Overview

Nebula Genomics offers direct-to-consumer and B2B whole-genome sequencing (WGS) services including 30x coverage, ancestry analysis, and data privacy management using blockchain. The company is not a drug developer and does not run therapeutic clinical trials; primary results are measured by the number of users and partnerships with biopharma for genomic data-enabled research.[1][2][3][4][7][8]

Industry: Molecular Diagnostics

Partnerships

BGI (MGI DNBSeq technology and sequencing centers)EMD Serono/Merck KGaA (data access and patient sequencing for lung cancer research)Oasis Labs (privacy and data control partnership with blockchain-based platform Parcel)

Beyond the preview

Go deeper on Nebula Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nebula Genomics.

Explore the full profile